Alnylam Pharmaceuticals, Inc. A1LN34.SA Stock
Alnylam Pharmaceuticals, Inc. Price Chart
Alnylam Pharmaceuticals, Inc. A1LN34.SA Financial and Trading Overview
| Alnylam Pharmaceuticals, Inc. stock price | 38.52 BRL |
| Previous Close | 47.53 BRL |
| Open | 0 BRL |
| Bid | 48.37 BRL x N/A |
| Ask | 49.98 BRL x N/A |
| Day's Range | 0 - 0 BRL |
| 52 Week Range | 0 - 63.96 BRL |
| Volume | 0 BRL |
| Avg. Volume | 0 BRL |
| Market Cap | 120.27B BRL |
| Beta (5Y Monthly) | 0.478521 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9 BRL |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
A1LN34.SA Valuation Measures
| Enterprise Value | 5.17B BRL |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 105.18562 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.522 |
| Enterprise Value/EBITDA | -6.996 |
Trading Information
Alnylam Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 0.478521 |
| 52-Week Change | 34.26% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 63.96 BRL |
| 52 Week Low | 0 BRL |
| 50-Day Moving Average | 47.47 BRL |
| 200-Day Moving Average | 53.89 BRL |
A1LN34.SA Share Statistics
| Avg. Volume (3 month) | 0 BRL |
| Avg. Daily Volume (10-Days) | 0 BRL |
| Shares Outstanding | 2.49B |
| Float | 123.83M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -93.13% |
| Operating Margin (ttm) | -68.92% |
| Gross Margin | 83.55% |
| EBITDA Margin | -64.63% |
Management Effectiveness
| Return on Assets (ttm) | -14.43% |
| Return on Equity (ttm) | -1500.66% |
Income Statement
| Revenue (ttm) | 1.14B BRL |
| Revenue Per Share (ttm) | 9.33 BRL |
| Quarterly Revenue Growth (yoy) | 49.70% |
| Gross Profit (ttm) | 868.6M BRL |
| EBITDA | -739073984 BRL |
| Net Income Avi to Common (ttm) | -1064915968 BRL |
| Diluted EPS (ttm) | -2.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.07B BRL |
| Total Cash Per Share (mrq) | 16.63 BRL |
| Total Debt (mrq) | 1.32B BRL |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.773 |
| Book Value Per Share (mrq) | -2.087 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -536556000 BRL |
| Levered Free Cash Flow (ttm) | -371195488 BRL |
Profile of Alnylam Pharmaceuticals, Inc.
| Country | Brazil |
| State | MA |
| City | Cambridge |
| Address | 675 West Kendall Street |
| ZIP | 02142 |
| Phone | 617 551 8200 |
| Website | https://www.alnylam.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2002 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Q&A For Alnylam Pharmaceuticals, Inc. Stock
What is a current A1LN34.SA stock price?
Alnylam Pharmaceuticals, Inc. A1LN34.SA stock price today per share is 38.52 BRL.
How to purchase Alnylam Pharmaceuticals, Inc. stock?
You can buy A1LN34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alnylam Pharmaceuticals, Inc.?
The stock symbol or ticker of Alnylam Pharmaceuticals, Inc. is A1LN34.SA.
Which industry does the Alnylam Pharmaceuticals, Inc. company belong to?
The Alnylam Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Alnylam Pharmaceuticals, Inc. have in circulation?
The max supply of Alnylam Pharmaceuticals, Inc. shares is 2.53B.
What is Alnylam Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Alnylam Pharmaceuticals, Inc. PE Ratio is now.
What was Alnylam Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Alnylam Pharmaceuticals, Inc. EPS is -0.9 BRL over the trailing 12 months.
Which sector does the Alnylam Pharmaceuticals, Inc. company belong to?
The Alnylam Pharmaceuticals, Inc. sector is Healthcare.